---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-029363"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:06:42.124979+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt

## Summary
- Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.
- R&D expenses surged to $237,501 from $48,500, driven by wages $161,875 and supplies $75,626.
- Cash remains $1; total assets $180,708; current liabilities $1,403,120 (including $1.31M due to parent BriaCell).
- Shareholders' deficit $1,390,648; accumulated deficit $1,425,163; going concern uncertainty noted as dependent on BriaCell funding.
- No auditor review performed; warrants liability $168,236 with Black-Scholes valuation.

## SEC filing metadata
- accession: 0001493152-25-029363
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315225029363/0001493152-25-029363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315225029363/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-029363
- JSON: https://secwatch.observer/filing/0001493152-25-029363.json
- Plain text: https://secwatch.observer/filing/0001493152-25-029363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.